Dynavax Technologies | DVAX - PE Price to Earnings

Stock Price
9.71
Daily Change
-0.36 -3.53%
Monthly
-7.35%
Yearly
-10.72%
Q3 Forecast
9.98

Dynavax Technologies reported $47.66 in PE Price to Earnings for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 918.45M
Cash and Equivalent USD 99.1M
Cost of Sales USD 14.04M
Current Assets USD 785.71M
Current Liabilities USD 118.23M
Debt USD 260.51M
EBIT USD 10.86M
EBITDA USD -21.59M
Employees 405
EPS Earnings Per Share USD 0.14
Equity Capital and Reserves USD 494.16M
Gross Profit on Sales USD 78.57M
Interest Expense on Debt USD 1.64M
Interest Income USD 7.74M
Loan Capital USD 220.75M
Market Capitalization USD 1.27B
Net Income USD 18.72M
Operating Expenses USD 81.01M
Operating Profit USD 10.86M
Ordinary Share Capital USD 117.23M
PE Price to Earnings USD 47.66
Pre-Tax Profit USD 21.22M
Sales Revenues USD 95.44M
Selling and Administration Expenses USD 41.54M
Stock USD 75.69M
Trade Creditors USD 2.7M
Trade Debtors USD 73.35M

Pe Change Date
AbbVie USD 18.41 69.26 Jun/2025
Adma Biologics USD 21.68 1.37 Jun/2025
Amgen USD 12.51 28.7 Jun/2025
AstraZeneca USD 20.04 12.31 Jun/2025
Biogen USD 12.41 0.17 Jun/2025
BioMarin Pharmaceutical USD 15.13 7.26 Jun/2025
Bristol-Myers Squibb USD 17.27 3.22 Jun/2025
Dynavax Technologies USD 47.66 38.52 Jun/2025
Gilead Sciences USD 15.39 279.48 Jun/2025
Glaxosmithkline GBP 18.39 3.81 Jun/2025
Merck USD 8.58 4.74 Jun/2025
Neurocrine Biosciences USD 42.61 5.9 Jun/2025
Novartis USD 15.89 3.03 Jun/2025
Pfizer USD 9.12 8.86 Jun/2025
Regeneron Pharmaceuticals USD 13.35 3.19 Jun/2025
Roche Holding CHF 19.32 1.87 Jun/2024
Sarepta Therapeutics USD 27.27 0 Jun/2025
TG Therapeutics USD 88.77 52.63 Jun/2025
Vertex Pharmaceuticals USD 27.81 3.5 Jun/2025